LXRX
Lexicon Pharmaceuticals Inc
1.70$
-4.4%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -25,690.7% | -7,200.6% | -4,878.8% | -2,947.2% | -3,063.9% | -80.9% | -3,468.9% | 58.9% | -168.1% | -313.7% | -69.8% | -3,456.9% | -192.2% | |
| 93.2% | 20.9% | 12.7% | 8.4% | 7.2% | 0.5% | 13.9% | 0.6% | 1.1% | 2.1% | 0.5% | 30.6% | 1.4% | |
| 2,406.2% | 457.5% | 380.7% | 295.0% | 160.1% | 5.8% | 241.1% | 11.1% | 24.3% | 51.6% | 14.6% | 926.9% | 38.0% | |
| 4,846.9% | -609.3% | -1,015.0% | 258.0% | 553.7% | 44.3% | -1,524.3% | 38.8% | -100.9% | -82.8% | -77.8% | -274.7% | -89.6% | |
| 51.2% | 0.0% | 0.0% | 15.2% | 17.5% | 1.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| -24,275.3% | 7,392.9% | -9,754.3% | -748.2% | 3,055.4% | 202.2% | 3,215.7% | 53.6% | 367.5% | 87.9% | -333.0% | -12,532.4% | -241.2% | |
| -130.2% | 30.1% | -153.1% | 0.0% | 0.0% | 0.0% | -45.3% | – | – | 0.0% | – | – | – | |
| – | – | – | – | 0.0% | 0.0% | 0.0% | -155.9% | 0.0% | -54.6% | -23.7% | 106.8% | -17.5% | |
| -129.6% | -0.1% | 21,184.3% | -0.9% | -52.3% | -0.4% | -45.3% | -155.9% | 0.0% | -53.3% | 420.6% | 12,752.0% | 419.8% | |
| -50,095.7% | 192.2% | 6,551.2% | -3,696.2% | -60.9% | 120.9% | -298.6% | -43.4% | 199.5% | -279.1% | 17.8% | -3,237.3% | -13.7% | |
| -25,742.0% | -7,200.6% | -4,878.8% | -2,962.4% | -3,081.5% | -82.7% | -3,468.9% | 58.9% | -168.1% | -313.7% | -69.8% | -3,456.9% | -192.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.